Skip to main content

Table 1 Characteristics of patients and platforms in included studies.

From: Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer

Data set

chip

# probes

Patients, country, nodal statusa

outcomeb

Adjuvant systemic treatmentc

HUMAC [1]

spotted

oligonucleotides

29K

n = 60, DK

N-, low-malignant

metastasis

nil

Huang [2]

Affymetrix

95av2

12K

n = 52, Taiwan

N+

relapse

ct

Sotiriou 2003 [3]

Spotted

cDNA

7.6K

n = 99, UK

N+/N-

relapse

et, ct

Sotiriou 2006 [4]

Affymetrix

HG-133A

22K

n = 179 S (Uppsala), UK

N+/N-

dm

et

Rotterdam [5]

Affymetrix

HG-133A

22K

n = 286, NL

N-

dm

nil

Amsterdam [6]

Rosetta

25K

n = 295, NL

N+/N-

dm

nil, ct, et

Uppsala [7]

Affymetrix

HG133A+B

44K

N = 236, S (Uppsala)

N+/N-

death from breast cancer

nil, ct, et

Stockholm [8]

Affymetrix

HG-133A+B

44K

n = 159, S (Stockholm)

N+/N-

relapse

nil, ct, et

  1. a: n, number of patients included; N+, positive nodal status; N-, negative nodal status; DK, Denmark; UK, United Kingdom; NL, the Netherlands; S, Sweden.
  2. b: dm, distant metastasis,
  3. c: ct, chemotherapy, et: endocrine therapy